Skip to content

Study · Systematic review · 2026

19 results

GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.

Gupta AK, Teasell EM, Economopoulos V, Mirmirani P

Science progress17 Apr 2026Cited by 5 (Europe PMC)

PMID41998799 (opens in a new tab)PMCIDPMC13100445 (opens in a new tab)DOI10.1177/00368504261444578 (opens in a new tab)PepBankPUB-41998799
Read at sourcePubMedAsk about this study
Jump to 19 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study19

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewSafety outcome

    Among GLP-1 users included in the review, semaglutide was associated with one of the highest reported hair-loss incidence rates across agents.

    In plain wordsAmong GLP-1 users in the review, semaglutide had one of the highest reported hair-loss incidence rates across drugs.

    Peptide
    Semaglutide
    Outcome
    IncreaseHair loss incidence
    Study

    n: not reported in source

    Comparator
    Other GLP-1 receptor agonists
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    3 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.
  2. 02HumanSystematic reviewSafety outcome

    Among GLP-1 users included in the review, tirzepatide was associated with one of the highest reported hair-loss incidence rates across agents.

    In plain wordsAmong GLP-1 users in the review, tirzepatide had one of the highest reported hair-loss incidence rates across drugs.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHair loss incidence
    Study

    n: not reported in source

    Comparator
    Other GLP-1 receptor agonists
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    3 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.
  3. 03HumanSystematic reviewSafety outcome

    Among GLP-1 users included in the review, tirzepatide was most frequently linked to telogen effluvium.

    In plain wordsAmong GLP-1 users in the review, tirzepatide was most frequently linked to telogen effluvium.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedTelogen effluvium
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tirzepatide, associated with the greatest magnitude of weight loss, was most frequently linked to telogen effluvium.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.
  4. 04HumanSystematic reviewSafety outcome

    Among users included in the review, semaglutide hair-loss associations appeared dose-dependent, with doses below 2mg weekly rarely implicated and higher obesity-treatment doses more commonly associated.

    In plain wordsAmong users in the review, semaglutide hair-loss reports appeared more common at higher obesity-treatment doses than below 2mg weekly.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedDose-related hair loss
    Study

    n: not reported in source

    Comparator
    Semaglutide doses < 2mg weekly
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    < 2mg weekly; unspecified higher obesity-treatment dosesAs given in this study (human).

    Source sentences

    Summary
    Hair loss associated with semaglutide appeared to be dose-dependent, with doses < 2mg weekly rarely implicated while higher obesity-treatment doses were more commonly associated with hair loss.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.
  5. 05HumanSystematic reviewSafety outcome

    Among GLP-1 users included in the review, semaglutide had more frequent pharmacovigilance hair-loss signal detection across agents.

    In plain wordsAmong GLP-1 users in the review, semaglutide had more frequent hair-loss signal detection than other GLP-1 drugs.

    Peptide
    Semaglutide
    Outcome
    IncreasePharmacovigilance signal detection for hair loss
    Study

    n: not reported in source

    Comparator
    Other GLP-1 receptor agonists
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    3 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.
  6. 06HumanSystematic reviewSafety outcome

    Among GLP-1 users included in the review, tirzepatide had more frequent pharmacovigilance hair-loss signal detection across agents.

    In plain wordsAmong GLP-1 users in the review, tirzepatide had more frequent hair-loss signal detection than other GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    IncreasePharmacovigilance signal detection for hair loss
    Study

    n: not reported in source

    Comparator
    Other GLP-1 receptor agonists
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    3 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.

Studies that did not test the peptide alone13

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    Among GLP-1 users included in the review, pooled liraglutide, dulaglutide, lixisenatide and exenatide typically had lower reported hair-loss risk than semaglutide and tirzepatide.

    In plain wordsAmong GLP-1 users in the review, liraglutide and three other drugs typically had lower reported hair-loss risk than semaglutide and tirzepatide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHair loss risk
    Study

    n: not reported in source

    Comparator
    Semaglutide and tirzepatide
    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.
    3 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 08HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    Among GLP-1 users included in the review, androgenetic alopecia was a predominant reported hair-loss subtype across agents, although classification was infrequent.

    In plain wordsAmong GLP-1 users in the review, androgenetic alopecia was a predominant reported hair-loss subtype across drugs.

    Peptide
    Semaglutide
    Outcome
    Not applicablePredominant androgenetic alopecia subtype
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Although infrequently classified overall, androgenetic alopecia and telogen effluvium were the predominant subtypes of hair loss reported.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 09HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    Among GLP-1 users included in the review, androgenetic alopecia was a predominant reported hair-loss subtype across agents, although classification was infrequent.

    In plain wordsAmong GLP-1 users in the review, androgenetic alopecia was a predominant reported hair-loss subtype across drugs.

    Peptide
    Liraglutide
    Outcome
    Not applicablePredominant androgenetic alopecia subtype
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Although infrequently classified overall, androgenetic alopecia and telogen effluvium were the predominant subtypes of hair loss reported.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 10HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    Among GLP-1 users included in the review, androgenetic alopecia was a predominant reported hair-loss subtype across agents, although classification was infrequent.

    In plain wordsAmong GLP-1 users in the review, androgenetic alopecia was a predominant reported hair-loss subtype across drugs.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePredominant androgenetic alopecia subtype
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Although infrequently classified overall, androgenetic alopecia and telogen effluvium were the predominant subtypes of hair loss reported.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  5. 11HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    Among GLP-1 users included in the review, telogen effluvium was a predominant reported hair-loss subtype across agents, although classification was infrequent.

    In plain wordsAmong GLP-1 users in the review, telogen effluvium was a predominant reported hair-loss subtype across drugs.

    Peptide
    Semaglutide
    Outcome
    Not applicablePredominant telogen effluvium subtype
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Although infrequently classified overall, androgenetic alopecia and telogen effluvium were the predominant subtypes of hair loss reported.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 12HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    Among GLP-1 users included in the review, telogen effluvium was a predominant reported hair-loss subtype across agents, although classification was infrequent.

    In plain wordsAmong GLP-1 users in the review, telogen effluvium was a predominant reported hair-loss subtype across drugs.

    Peptide
    Liraglutide
    Outcome
    Not applicablePredominant telogen effluvium subtype
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Although infrequently classified overall, androgenetic alopecia and telogen effluvium were the predominant subtypes of hair loss reported.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 13HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    Among GLP-1 users included in the review, telogen effluvium was a predominant reported hair-loss subtype across agents, although classification was infrequent.

    In plain wordsAmong GLP-1 users in the review, telogen effluvium was a predominant reported hair-loss subtype across drugs.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePredominant telogen effluvium subtype
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Although infrequently classified overall, androgenetic alopecia and telogen effluvium were the predominant subtypes of hair loss reported.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  8. 14HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    Among GLP-1 users included in the review, females appeared disproportionately affected by reported hair loss across agents.

    In plain wordsAmong GLP-1 users in the review, females appeared disproportionately affected by reported hair loss across drugs.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedFemale disproportion in reported hair loss
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Females appeared to be disproportionately affected.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  9. 15HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    Among GLP-1 users included in the review, females appeared disproportionately affected by reported hair loss across agents.

    In plain wordsAmong GLP-1 users in the review, females appeared disproportionately affected by reported hair loss across drugs.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedFemale disproportion in reported hair loss
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Females appeared to be disproportionately affected.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  10. 16HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    Among GLP-1 users included in the review, females appeared disproportionately affected by reported hair loss across agents.

    In plain wordsAmong GLP-1 users in the review, females appeared disproportionately affected by reported hair loss across drugs.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedFemale disproportion in reported hair loss
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Females appeared to be disproportionately affected.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  11. 17HumanNot a test of Semaglutide aloneSystematic reviewOther

    Among GLP-1 users included in the review, rapid weight loss emerged as a potential contributor to hair loss across agents, particularly telogen effluvium.

    In plain wordsAmong GLP-1 users in the review, rapid weight loss was a potential contributor to hair loss, particularly telogen effluvium.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedRapid weight loss as a potential contributor to telogen effluvium
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Rapid weight loss emerged as a potential contributor, particularly for telogen effluvium.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  12. 18HumanNot a test of Liraglutide aloneSystematic reviewOther

    Among GLP-1 users included in the review, rapid weight loss emerged as a potential contributor to hair loss across agents, particularly telogen effluvium.

    In plain wordsAmong GLP-1 users in the review, rapid weight loss was a potential contributor to hair loss, particularly telogen effluvium.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedRapid weight loss as a potential contributor to telogen effluvium
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Rapid weight loss emerged as a potential contributor, particularly for telogen effluvium.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  13. 19HumanNot a test of Tirzepatide aloneSystematic reviewOther

    Among GLP-1 users included in the review, rapid weight loss emerged as a potential contributor to hair loss across agents, particularly telogen effluvium.

    In plain wordsAmong GLP-1 users in the review, rapid weight loss was a potential contributor to hair loss, particularly telogen effluvium.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedRapid weight loss as a potential contributor to telogen effluvium
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Rapid weight loss emerged as a potential contributor, particularly for telogen effluvium.
    4 context sentences
    Summary · context
    MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384).
    Summary · context
    Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133 studies identified, 24 met inclusion criteria.
    Summary · context
    Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies.
    Summary · context
    In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.